IN THE UNITED STATES DESIGNATION APPENDENT STATES OF THE 2006

Intern	ational .	Application No.	:	PCT/EP2004/007531
Intern	alional 1	Filing Date	:	08 July 2004 (08.07.2004)
Priorit	ty Dale(s) Claimed	:	11 July 2003 (11.07.2003)
Applie	cant(s) (DO/EO/US)	:	Daria ONICHTCHOUK
		3 SECRETED TREA TABODIC SYNDRO		EATIC DISEASES AND/OR OBESITY
INFO	RMAT	TON DISCLOSURE	STATEMENT	T UNDER 37 CPR §§ 1.56, 1.97 and 1.98
P.O. E	3ox 145	r for Patents 0 'A 22313-1450		
Sir:				
and 1.	This in 98 as fo		statement is ma	to in accordance with 37 C.F.R. §§ 1.56, 1.97
Timin	g and F	ees	\wedge	
\boxtimes		37 C.F.R. § 1.97(b), sure statement is filed:		meet is required for filing this information
		within three months under § 1.53(d);	of the filing date	e of a national application other than a CPA
	\boxtimes	within three months application, OR	of the actual i	filing date of the national phase of a PCT
		before the mailing of RCE).	a first substant	ive office action (including after filing of an
		37 C.F.R. § 1.97(c), the		disclosure statement is filed after the periods the mailing date of:
,		a final rejection unde termination of prosec a notice of allowance	cution, e.g. Ex I	Parte Quayle, M.P.E.P § 609(B)(2); QR

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
/	\		a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		afinal	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P (609(B)(2);
		OR a r	nonce of allowance under 37 C.F.R. § 1.311;
	AND i	is filed	on or before payment of the issue fee; AND is accompanied by:
		the sta \$180.0	tement as specified in 37 C.F.R. § 1.97(c) as set forth below, and the fee of 10 under 37 C.F.R. § 1.17(p).
Statem	ents Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 Cf. R.§ 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited 1	Materia	ls	
		angest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	\boxtimes		s of materials listed but not attached were cited in an international search dated <u>April 28, 2005</u> .
		Not re	quired by 37 CFR § 1.98.
		Copies	s of the materials listed are attached (except for the foregoing).
•			2

Non-English	Language References
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	X document of particular relevance when it is taken alone document of particular relevance when it is combined with another such document
	A = document defining the general state of the art
	O = non written disclosure P = interculated document
	T = document cited to understand the theory or principle underlying the
	invention
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
	D = cited in the application
	L = cited for another reason
	& = publication of member of same patent family
	Translation of other relevant information on foreign search report
Other Inform	nation /
Payment of I	Fees Due (If Any):
☐ A che	eck for \$ covering the fee identified above is attached.
Pleas	e charge to Deposit Account No. 13-3402 \$ for the fee identified above.

The Commissioner is hereby authorized to charge of credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, XELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: WEICKM-00

Date: January 11, 2006

AJZ:ssr

Please type a plus sign (+) insida this box

PTO/SB/08A (08-00)

Approved for use through 10/3 1/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPATMENT OF COMMERCE
Urder the Paperwork Reduction Act of 1995, no persons are required to respond b a collection of information unless contrains a walk operation and the contrainment of the co Complete 11 10 10 15 6427 Substituta for form 1449A/PTO Application Number INFORMATION DISCLOSURE Filing Data 08 July 2004 (08.07.2004) STATEMENT BY APPLICANT First Nemed Inventor Daria ONICHTCHOUK Group Art Unit unknown (use as many sheets as necessary) unknown Sheet of WEICKM-0051 Attorney Docket Number

			U.S. P	ATENT DOCUMENTS	
		U.S. Patent Docum	nent		
Examiner Initials *	Cite No.1	Number	Kind Coda ² (if known)	Nama of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	001	2002/132978	A1	GERBER, ET AL.	09-19-2002
	002	2002/182198	A1	COMMISSIONG, ET AL.	12-05-2002
		,			

			FOREIG	N PATENT DOCUMENTS			
	Foreign Petent Document				Detect Publication of	Pages, Columns, Lines,	
Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Citad Document MM-DD-YYYY	Passages or Relevant Figures Appear	T*
003	wo	02/074956	A	NEUROPHARMA INC, ET	09-26-2002		002
004	wo	01/19851			03-22-2001		
005	wo	02/079246	A	BOUGUELERET, ET AL.	10-10-2002		
			-				
	003 004	Otto No.1 Office2 O03 WO O04 WO	Cite No.¹ Office³ Number⁴ 003 WO 02/074956 004 WO 01/19851			Cite No. Office Number Kind Code Number Applicant of Cited Document MM-DD-YYYY Mms of Passities or Applicant of Cited Document MM-DD-YYYYY MM-DD-YYYYY MM-DD-YYYYY MM-DD-YYYYY MM-DD-YYYYY MM-DD-YYYYYY MM-DD-YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY	

Examiner Signature	Date Considered		
-----------------------	--------------------	--	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by tha two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the VITEO Satisfacts 31-3). Foll departies a period occurred to the process of the document of the Process of the Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hur Statement: This form is estimated to take 2.0 hours to complete. Time well-sury depending upon the reseast of the individual seast August comments on the restructed forms upon a required to complete this form should be sent to the Chief formation Office, U.S. Patient and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patients, P.O. Box 1450, Alexandria, V. 202311-1450.

IAP20 Rec'd POTIFIC 11 JAN 2006

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patient and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a codection of information uniess it contains a radii GMB control number

Substitute f	or form 1449A/PTC	,			Complete if Known
l			01.001105	Application Number	USNE of PCT/EP2004/0075317
			CLOSURE	Filing Date	08 July 2004 08 07 2004)
STAT	EMENT B	Y A	PPLICANT	First Named Inventor	Daria ONICHTCHOUK
				Group Art Unit	unknown
(use as many she	eets as	necessary)	Examiner Name	unknown
Sheet	2	of	2	Attorney Docket Number	WEICKM-0051

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the erticle (when eppropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т,
inidas :		SHRIDHAR VET AL: "MUTATIONS IN THE AGRININE-RICH PROTEIN GRUE (ARP) IN PANCREATIC CANCER." ONCOGENE 8 MAY 1997, vol. 14, no. 18, pages 2213-2216, XP001204720, ISSN: 0950-9232, cited in the application - the whole document	

				$\overline{}$
Examiner Signature	/Christine Saoud/	Date Considered	09/29/2008]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case, Any comments on the amount of time you are required to complete be form should be sent to the Chef Information Officer, U.S. Patent and Tradsmark.

+ Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandris, VA 22313-1460.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.